X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Default Magnification Type | A code sequence identifying the default magnification type. | ILX:0102974 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Default Printer Resolution ID | The printer's default resolution identification. Defined Terms are the same as Requested Resolution ID (2020,0050). | ILX:0102975 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Default Smoothing Type | Printer's default smoothing type. | ILX:0102976 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Deferasirox | Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. Pharmacology: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain. Mechanism of action: Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. Drug type: Approved. Investigational. Small Molecule. Drug category: Iron Chelating Agents | ILX:0102977 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Deferoxamine | Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. (PubChem) Pharmacology: Deferoxamine, otherwise known as desferrioxamine or desferal, is a chelating agent used to remove excess iron or aluminum from the body. It acts by binding free iron or aluminum in the bloodstream and enhancing its elimination in the urine. By removing excess iron or aluminum, the agent reduces the damage done to various organs and tissues, such as the liver. Mechanism of action: Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum. Drug type: Approved. Small Molecule. Drug category: Chelating agent. Iron Chelating Agents. Siderophores | ILX:0102978 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Deficit Syndrome Score Sheet | The SDS is a symptom assessment tool, which assesses negative symptoms in schizophrenia. Six core items of the deficit syndrome (restricted affect; diminished emotional range; poverty of speech; curbing of interests; diminished sense of purpose; and diminished social drive) are rated on a 5-point scale, 0 | ILX:0102979 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Deformed | Distorted in form. | ILX:0102980 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Degenerate | ILX:0102981 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Degeneration | Structure which deteriorates or is lost over time. | ILX:0102982 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Degenerative Retinoschis | Splitting of the RETINA into two layers at the level of the outer plexiform layer, beginning as a cystic degeneration in the extreme retinal periphery. It usually occurs after 40 years of age and is generally not progressive. | ILX:0102983 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Degradative Enzyme | ILX:0102984 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Degree of Dilation | The degree of the dilation in mm. | ILX:0102985 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dehydrated | The removal of water from an entity. | ILX:0102986 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Delaminated | ILX:0102987 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Delavirdine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. (PubChem) Pharmacology: Delavirdine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdine. Mechanism of action: Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site. Drug type: Approved. Small Molecule. Drug category: Anti-HIV Agents. Nonnucleoside Reverse Transcriptase Inhibitors. Reverse Transcriptase Inhibitors | ILX:0102988 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Delayed | A duration which starts later than the natural start time. | ILX:0102989 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Delayed discounting task | A task for identifying preferences over tradeoffs between costs and benefits occurring at different times. | ILX:0102990 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Delayed match to sample task | Subjects view an item(s). After a brief delay a probe item is presented and subjects are asked to recall if the probe item was presented before the delay (during encoding). Stimuli can be words, pictures, or abstract patterns. | ILX:0102991 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Delayed matching to sample paradigm | A behavioral paradigm in which subjects view three or more items.. After a brief delay a probe item is presented and subjects are asked to recall if the probe item was presented in the the previous list. Stimuli can be words, pictures, or abstract patterns. If the stimuli are letters, the task is coded as a Sternberg Task. | ILX:0102992 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Delayed nonmatch to sample task | A task in which an target is presented and then removed from view. This target must be maintained in working memory for a delay, after which it is presented with non-target(s). The participant's task is to identify the non-target. | ILX:0102993 | 5 | scicrunch | 09/07/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X